https://doi.org/10.4049/jimmunol.157.12.5221
M
Michael Coffey
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
110
Papers
4.6K
Citations
40
h-index
61
i10-index
Michael Coffey is an academic researcher from Poseida Therapeutics (United States). The author has contributed to research in topics: Asthma and respiratory diseases & Classical Antiquity Studies & Toxoplasma gondii Research Studies. The author has an h-index of 40, co-authored 94 publications.
ORCID: 0000-0002-8025-4558Papers by this author
worksLeukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities
1996 · The Journal of Immunology · 273 citations
TNF-α Inhibits HIV-1 Replication in Peripheral Blood Monocytes and Alveolar Macrophages by Inducing the Production of RANTES and Decreasing C-C Chemokine Receptor 5 (CCR5) Expression
1999 · The Journal of Immunology · 120 citations
https://doi.org/10.4049/jimmunol.163.7.3653
5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus
1996 · The Journal of Immunology · 71 citations
https://doi.org/10.4049/jimmunol.157.1.393
Pilot Study Program, Great Lakes Shoreland Damage Study. Appendix V. Shoreline Damage Survey: An Appraisal with Recommendations.
1976 · Defense Technical Information Center (DTIC) · 0 citations
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
2025 · Nature Communications · 0 citations
https://doi.org/10.1038/s41467-025-65267-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat